Upregulation of IGF1 by tumor-associated macrophages promotes the proliferation and migration of epithelial ovarian cancer cells

Liu,Li; Wang,Xinjing; Li,Xiaoduan; Wu,Xiaoli; Tang,Meiling; Wang,Xipeng

doi:10.3892/or.2017.6148

Upregulation of IGF1 by tumor-associated macrophages promotes the proliferation and migration of epithelial ovarian cancer cells

Authors:
- Li Liu
- Xinjing Wang
- Xiaoduan Li
- Xiaoli Wu
- Meiling Tang
- Xipeng Wang
View Affiliations

Affiliations: Department of Gynecology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai 201204, P.R. China
Published online on: December 11, 2017 https://doi.org/10.3892/or.2017.6148
Pages: 818-826

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer (OC), of which epithelial ovarian cancer (EOC) is the most common, is the deadliest gynecological tumor because of the difficulties in detection at early stages, and metastasis and chemoresistance at advanced stages. Tumor-associated macrophages (TAMs) differentiate through alternative pathways and play important roles in tumor growth and metastasis. However, the underlying mechanism remains unclear. Here, we established a mouse TAM model using bone marrow monocytes and conditioned medium (CM) of TAMs to culture ID8 mouse EOC cells. The results showed that TAM CM accelerated the proliferation and migration of ID8 cells. In a previous study, gene chip analysis showed that human TAMs expressed significantly higher levels of insulin-like growth factor‑1 (IGF1) than undifferentiated M0 myeloid cells. In the present study, we observed that the IGF1 level was higher in human EOC specimens than that in benign ovarian tumor specimens, and further analysis showed that a higher level of IGF1 was related to more advanced clinical stage and liver metastasis. Therefore, we hypothesized that TAMs may accelerate the proliferation and migration of EOC cells by upregulating IGF1. As expected, increased IGF1 expression at both the mRNA and protein levels was observed in ID8 cells cultured with TAM CM, whereas blockade of the IGF1 pathway in ID8 cells with an IGF1 neutralizing antibody effectively reversed the promotion of proliferation and migration. Finally, we inhibited the phosphorylation of insulin-like growth factor‑1 receptor (IGF1R) and its downstream molecules Akt and Erk with the IGF1R inhibitor linsitinib, and observed that the treatment effectively suppressed the proliferation and migration of ID8 cells exposed to TAM CM. Thus, we demonstrated that TAMs may promote the growth and metastasis of EOC via the activation of the IGF1 pathway; thus, targeting the IGF1 pathway may be promising for EOC therapy.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
3	Colombo PE, Fabbro M, Theillet C, Bibeau F, Rouanet P and Ray-Coquard I: Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer. Crit Rev Oncol Hematol. 89:207–216. 2014. View Article : Google Scholar : PubMed/NCBI
4	Nagaraj AB, Joseph P and DiFeo A: miRNAs as prognostic and therapeutic tools in epithelial ovarian cancer. Biomarkers Med. 9:241–257. 2015. View Article : Google Scholar
5	Naora H and Montell DJ: Ovarian cancer metastasis: Integrating insights from disparate model organisms. Nat Rev Cancer. 5:355–366. 2005. View Article : Google Scholar : PubMed/NCBI
6	Son B, Lee S, Youn HS, Kim EG, Kim W and Youn BH: The role of tumor microenvironment in therapeutic resistance. Oncotarget. 8:3933–3945. 2017.PubMed/NCBI
7	Liu Y and Cao X: Characteristics and Significance of the Pre-metastatic Niche. Cancer Cell. 30:668–681. 2016. View Article : Google Scholar : PubMed/NCBI
8	Wu JS, Sheng SR, Liang XH and Tang YL: The role of tumor microenvironment in collective tumor cell invasion. Future Oncol. 13:991–1002. 2017. View Article : Google Scholar : PubMed/NCBI
9	Richards KE, Zeleniak AE, Fishel ML, Wu J, Littlepage LE and Hill R: Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells. Oncogene. 36:1770–1778. 2017. View Article : Google Scholar : PubMed/NCBI
10	Sugiyama K, Kajiyama H, Shibata K, Yuan H, Kikkawa F and Senga T: Expression of the miR200 family of microRNAs in mesothelial cells suppresses the dissemination of ovarian cancer cells. Mol Cancer Ther. 13:2081–2091. 2014. View Article : Google Scholar : PubMed/NCBI
11	Kim J and Bae JS: Tumor-associated macrophages and neutrophils in tumor microenvironment. Mediators Inflamm. 2016:60581472016. View Article : Google Scholar : PubMed/NCBI
12	Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, Rimoldi M, Biswas SK, Allavena P and Mantovani A: Macrophage polarization in tumour progression. Semin Cancer Biol. 18:349–355. 2008. View Article : Google Scholar : PubMed/NCBI
13	Zhang L, Zhang S, Yao J, Lowery FJ, Zhang Q, Huang WC, Li P, Li M, Wang X, Zhang C, et al: Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature. 527:100–104. 2015. View Article : Google Scholar : PubMed/NCBI
14	Kurahara H, Takao S, Maemura K, Mataki Y, Kuwahata T, Maeda K, Sakoda M, Iino S, Ishigami S, Ueno S, et al: M2-polarized tumor-associated macrophage infiltration of regional lymph nodes is associated with nodal lymphangiogenesis and occult nodal involvement in pN0 pancreatic cancer. Pancreas. 42:155–159. 2013. View Article : Google Scholar : PubMed/NCBI
15	Reinartz S, Schumann T, Finkernagel F, Wortmann A, Jansen JM, Meissner W, Krause M, Schwörer AM, Wagner U, Müller-Brüsselbach S, et al: Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: Correlation of CD163 expression, cytokine levels and early relapse. Int J Cancer. 134:32–42. 2014. View Article : Google Scholar : PubMed/NCBI
16	Lan C, Huang X, Lin S, Huang H, Cai Q, Wan T, Lu J and Liu J: Expression of M2-polarized macrophages is associated with poor prognosis for advanced epithelial ovarian cancer. Technol Cancer Res Treat. 12:259–267. 2013. View Article : Google Scholar : PubMed/NCBI
17	Pollard JW: Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 4:71–78. 2004. View Article : Google Scholar : PubMed/NCBI
18	Takaishi K, Komohara Y, Tashiro H, Ohtake H, Nakagawa T, Katabuchi H and Takeya M: Involvement of M2-polarized macrophages in the ascites from advanced epithelial ovarian carcinoma in tumor progression via Stat3 activation. Cancer Sci. 101:2128–2136. 2010. View Article : Google Scholar : PubMed/NCBI
19	Carroll MJ, Kapur A, Felder M, Patankar MS and Kreeger PK: M2 macrophages induce ovarian cancer cell proliferation via a heparin binding epidermal growth factor/matrix metalloproteinase 9 intercellular feedback loop. Oncotarget. 7:86608–86620. 2016.PubMed/NCBI
20	Iams WT and Lovly CM: Molecular pathways: Clinical applications and future direction of insulin-like growth factor-1 receptor pathway blockade. Clin Cancer Res. 21:4270–4277. 2015. View Article : Google Scholar : PubMed/NCBI
21	Dyer AH, Vahdatpour C, Sanfeliu A and Tropea D: The role of insulin-like growth factor 1 (IGF-1) in brain development, maturation and neuroplasticity. Neuroscience. 325:89–99. 2016. View Article : Google Scholar : PubMed/NCBI
22	Baserga R: The contradictions of the insulin-like growth factor 1 receptor. Oncogene. 19:5574–5581. 2000. View Article : Google Scholar : PubMed/NCBI
23	Zhang M, Hu Z, Huang J, Shu Y, Dai J, Jin G, Tang R, Dong J, Chen Y, Xu L, et al: A 3′-untranslated region polymorphism in IGF1 predicts survival of non-small cell lung cancer in a Chinese population. Clin Cancer Res. 16:1236–1244. 2010. View Article : Google Scholar : PubMed/NCBI
24	Soulitzis N, Karyotis I, Delakas D and Spandidos DA: Expression analysis of peptide growth factors VEGF FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. Int J Oncol. 29:305–314. 2006.PubMed/NCBI
25	Xu L, Zhou R, Yuan L, Wang S, Li X, Ma H, Zhou M, Pan C, Zhang J, Huang N, et al: IGF1/IGF1R/STAT3 signaling-inducible IFITM2 promotes gastric cancer growth and metastasis. Cancer Lett. 393:76–85. 2017. View Article : Google Scholar : PubMed/NCBI
26	Pacher M, Seewald MJ, Mikula M, Oehler S, Mogg M, Vinatzer U, Eger A, Schweifer N, Varecka R, Sommergruber W, et al: Impact of constitutive IGF1/IGF2 stimulation on the transcriptional program of human breast cancer cells. Carcinogenesis. 28:49–59. 2007. View Article : Google Scholar : PubMed/NCBI
27	Hirakawa T, Yashiro M, Doi Y, Kinoshita H, Morisaki T, Fukuoka T, Hasegawa T, Kimura K, Amano R and Hirakawa K: Pancreatic fibroblasts stimulate the motility of pancreatic cancer cells through IGF1/IGF1R sgnaling under hypoxia. PLoS One. 11:e01599122016. View Article : Google Scholar : PubMed/NCBI
28	Yaktapour N, Übelhart R, Schüler J, Aumann K, Dierks C, Burger M, Pfeifer D, Jumaa H, Veelken H, Brummer T, et al: Insulin-like growth factor-1 receptor (IGF1R) as a novel target in chronic lymphocytic leukemia. Blood. 122:1621–1633. 2013. View Article : Google Scholar : PubMed/NCBI
29	Terry KL, Tworoger SS, Gates MA, Cramer DW and Hankinson SE: Common genetic variation in IGF1, IGFBP1 and IGFBP3 and ovarian cancer risk. Carcinogenesis. 30:2042–2046. 2009. View Article : Google Scholar : PubMed/NCBI
30	Lau MT and Leung PC: The PI3K/Akt/mTOR signaling pathway mediates insulin-like growth factor 1-induced E-cadherin down-regulation and cell proliferation in ovarian cancer cells. Cancer Lett. 326:191–198. 2012. View Article : Google Scholar : PubMed/NCBI
31	Poljicanin A, Filipovic N, Vukusic Pusic T, Soljic V, Caric A, Saraga-Babic M and Vukojevic K: Expression pattern of RAGE and IGF-1 in the human fetal ovary and ovarian serous carcinoma. Acta Histochem. 117:468–476. 2015. View Article : Google Scholar : PubMed/NCBI
32	Torng PL, Lee YC, Huang CY, Ye JH, Lin YS, Chu YW, Huang SC, Cohen P, Wu CW and Lin CT: Insulin-like growth factor binding protein-3 (IGFBP-3) acts as an invasion-metastasis suppressor in ovarian endometrioid carcinoma. Oncogene. 27:2137–2147. 2008. View Article : Google Scholar : PubMed/NCBI
33	Koti M, Gooding RJ, Nuin P, Haslehurst A, Crane C, Weberpals J, Childs T, Bryson P, Dharsee M, Evans K, et al: Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer. BMC Cancer. 13:5492013. View Article : Google Scholar : PubMed/NCBI
34	Huang YF, Cheng WF, Wu YP, Cheng YM, Hsu KF and Chou CY: Circulating IGF system and treatment outcome in epithelial ovarian cancer. Endocr Relat Cancer. 21:217–229. 2014. View Article : Google Scholar : PubMed/NCBI
35	Li Y, Li Y, Zhang J, Zheng C, Zhu H, Yu H and Fan L: Circulating insulin-like growth factor-1 level and ovarian cancer risk. Cell Physiol Biochem. 38:589–597. 2016. View Article : Google Scholar : PubMed/NCBI
36	Gianuzzi X, Palma-Ardiles G, Hernandez-Fernandez W, Pasupuleti V, Hernandez AV and Perez-Lopez FR: Insulin growth factor (IGF) 1, IGF-binding proteins and ovarian cancer risk: A systematic review and meta-analysis. Maturitas. 94:22–29. 2016. View Article : Google Scholar : PubMed/NCBI
37	Lin Y, Wei C, Liu Y, Qiu Y, Liu C and Guo F: Selective ablation of tumor-associated macrophages suppresses metastasis and angiogenesis. Cancer Sci. 104:1217–1225. 2013. View Article : Google Scholar : PubMed/NCBI
38	Remmele W and Stegner HE: Immunhistochemischer Nachweis von Oestrogenrezeptoren (ER-ICA) in Mammakarzinomen. Frauenarzt. 28:41–43. 1987.(In German).
39	Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA, Thompson R, Schioppa T, Nemeth J, Vermeulen J, et al: Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res. 17:6083–6096. 2011. View Article : Google Scholar : PubMed/NCBI
40	Koblish HK, Hansbury MJ, Bowman KJ, Yang G, Neilan CL, Haley PJ, Burn TC, Waeltz P, Sparks RB, Yue EW, et al: Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. Mol Cancer Ther. 9:489–498. 2010. View Article : Google Scholar : PubMed/NCBI
41	Moughon DL, He H, Schokrpur S, Jiang ZK, Yaqoob M, David J, Lin C, Iruela-Arispe ML, Dorigo O and Wu L: Macrophage blockade using CSF1R inhibitors reverses the vascular leakage underlying malignant ascites in late-stage epithelial ovarian cancer. Cancer Res. 75:4742–4752. 2015. View Article : Google Scholar : PubMed/NCBI
42	Wang Z, Chen JQ, Liu JL and Tian L: Exosomes in tumor microenvironment: Novel transporters and biomarkers. J Transl Med. 14:2972016. View Article : Google Scholar : PubMed/NCBI
43	Goyne HE, Stone PJ, Burnett AF and Cannon MJ: Ovarian tumor ascites CD14+ cells suppress dendritic cell-activated CD4+ T-cell responses through IL-10 secretion and indoleamine 2,3-dioxygenase. J Immunother. 37:163–169. 2014. View Article : Google Scholar : PubMed/NCBI
44	Zhou H, Qian W, Uckun FM, Wang L, Wang YA, Chen H, Kooby D, Yu Q, Lipowska M, Staley CA, et al: IGF1 Receptor targeted theranostic nanoparticles for targeted and image-guided therapy of pancreatic cancer. ACS Nano. 9:7976–7991. 2015. View Article : Google Scholar : PubMed/NCBI
45	Ukaji T, Lin Y, Banno K, Okada S and Umezawa K: Inhibition of IGF-1-mediated cellular migration and invasion by migracin A in ovarian clear cell carcinoma cells. PLoS One. 10:e01376632015. View Article : Google Scholar : PubMed/NCBI